Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial-Reference-Cited by-同舟云学术

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial

Published:2023-01 Issue:1 Volume:88 Page:40-51
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Strober Bruce,Thaçi Diamant,Sofen Howard,Kircik Leon,Gordon Kenneth B.,Foley Peter,Rich Phoebe,Paul Carle,Bagel Jerry,Colston Elizabeth,Throup John,Kundu Sudeep,Sekaran Chitra,Linaberry Misti,Banerjee Subhashis,Papp Kim A.

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Dermatology

Reference18 articles.

1. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Sbidian;Cochrane Database Syst Rev,2017

2. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011;Armstrong;JAMA Dermatol,2013

3. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data;Armstrong;Dermatol Ther (Heidelb),2017

4. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain;Burke;Sci Transl Med,2019

5. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors;Chimalakonda;Dermatol Ther (Heidelb),2021

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topical treatment of tyrosine kinase 2 inhibitor through borneol-embedded hydrogel: Evaluation for preventive, therapeutic, and Recurrent management of psoriasis;Bioactive Materials;2024-11

2. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

3. Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis;Journal of Dermatological Treatment;2024-09

4. An integrated bioinformatics approach for unravelling the molecular insights into psoriasis pathology and therapeutics;Gene Reports;2024-09

5. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09